Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies
Abstract The established protocol for the management of acute myeloid leukemia (AML) has traditionally involved the administration of induction chemotherapy, followed by consolidation chemotherapy, and subsequent allogeneic stem cell transplantation for eligible patients. However, the prognosis for...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-01797-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571542524919808 |
|---|---|
| author | Ugochi Ebinama Binsah George |
| author_facet | Ugochi Ebinama Binsah George |
| author_sort | Ugochi Ebinama |
| collection | DOAJ |
| description | Abstract The established protocol for the management of acute myeloid leukemia (AML) has traditionally involved the administration of induction chemotherapy, followed by consolidation chemotherapy, and subsequent allogeneic stem cell transplantation for eligible patients. However, the prognosis for individuals with relapsed and refractory AML remains unfavorable. In response to the necessity for more efficacious therapeutic modalities, targeted immunotherapy has emerged as a promising advancement in AML treatment. This comprehensive review article specifically examines classical unconjugated and toxin-conjugated monoclonal antibodies, which are currently in the preclinical phase or undergoing evaluation in clinical trials. The review delves into the proposed mechanisms through which these monoclonal antibodies elicit anti-tumor activity and identifies the challenges associated with designing targeted immunotherapy. The review focuses on targeting specific antigens in AML, including FLT3/CD125, CLL-1, CD33, CD38, CD47, CD70, and CD123. |
| format | Article |
| id | doaj-art-ba436636875d481f970c55834ae405ad |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-ba436636875d481f970c55834ae405ad2025-02-02T12:30:37ZengSpringerDiscover Oncology2730-60112025-01-0116111510.1007/s12672-025-01797-9Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapiesUgochi Ebinama0Binsah George1Department of Internal Medicine, The University of Texas Health Sciences Center at Houston, McGovern Medical SchoolDivision of Hematology/Oncology, The University of Texas Health Sciences Center at Houston, McGovern Medical SchoolAbstract The established protocol for the management of acute myeloid leukemia (AML) has traditionally involved the administration of induction chemotherapy, followed by consolidation chemotherapy, and subsequent allogeneic stem cell transplantation for eligible patients. However, the prognosis for individuals with relapsed and refractory AML remains unfavorable. In response to the necessity for more efficacious therapeutic modalities, targeted immunotherapy has emerged as a promising advancement in AML treatment. This comprehensive review article specifically examines classical unconjugated and toxin-conjugated monoclonal antibodies, which are currently in the preclinical phase or undergoing evaluation in clinical trials. The review delves into the proposed mechanisms through which these monoclonal antibodies elicit anti-tumor activity and identifies the challenges associated with designing targeted immunotherapy. The review focuses on targeting specific antigens in AML, including FLT3/CD125, CLL-1, CD33, CD38, CD47, CD70, and CD123.https://doi.org/10.1007/s12672-025-01797-9Acute myeloid leukemiaMonoclonal antibodiesUnconjugated antibodyToxin-conjugated antibody |
| spellingShingle | Ugochi Ebinama Binsah George Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies Discover Oncology Acute myeloid leukemia Monoclonal antibodies Unconjugated antibody Toxin-conjugated antibody |
| title | Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies |
| title_full | Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies |
| title_fullStr | Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies |
| title_full_unstemmed | Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies |
| title_short | Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies |
| title_sort | revolutionizing acute myeloid leukemia treatment a systematic review of immune based therapies |
| topic | Acute myeloid leukemia Monoclonal antibodies Unconjugated antibody Toxin-conjugated antibody |
| url | https://doi.org/10.1007/s12672-025-01797-9 |
| work_keys_str_mv | AT ugochiebinama revolutionizingacutemyeloidleukemiatreatmentasystematicreviewofimmunebasedtherapies AT binsahgeorge revolutionizingacutemyeloidleukemiatreatmentasystematicreviewofimmunebasedtherapies |